Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast ...
Bristol Myers Squibb beat Q4 estimates with $12.34 billion revenue and $1.67 EPS. 2025 guidance lags expectations amid ...
BioPharma Dive1 日
Bristol Myers, bracing for key patent losses, deepens cost-cutting plan
The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies ...
Zacks.com on MSN1 日
BMY Q4 Earnings and Sales Beat Estimates, Shares Down on 2025 Outlook
Bristol-Myers Squibb Company BMY reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.67, which beat the ...
Will Non-COVID Drugs Drive PFE's Top Line in Q4 Earnings?
Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the fourth quarter.